Citrate salt, pharmaceutical compositions, and methods of making and using the same
The present disclosure features citrate salts and pharmaceutical compositions useful for the treatment of BAF complex-related disorders. Also disclosed are methods for preparing compounds.
1. A citrate salt of the compound of Formula I:
2. A pharmaceutical composition comprising the citrate salt of claim 1 .
3. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is liquid.
4. The pharmaceutical composition of claim 2 , further comprising a buffer.
5. The pharmaceutical composition of claim 4 , wherein the buffer is a citrate buffer.
6. The pharmaceutical composition of claim 2 , wherein pH of the pharmaceutical composition is 3.5 to 5.5.
7. The pharmaceutical composition of claim 2 , further comprising a cyclodextrin-based solubilizer.
8. The pharmaceutical composition of claim 7 , wherein the cyclodextrin-based solubilizer is sulfobutylether-β-cyclodextrin.
9. The pharmaceutical composition of claim 2 , further comprising saline.
10. The pharmaceutical composition of claim 9 , wherein the saline is an isotonic saline.
11. A method of treating a subject having synovial sarcoma, the method comprising administering to the subject an effective amount of the citrate salt of claim 1 .
12. A method treating a viral infection related to BAF47 in a subject in need thereof, the method comprising administering to the subject an effective amount of the citrate salt of claim 1 .